drugset / Trial / NCT04138992
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To verify the clinical efficacy and safety of bevacizumab in treating local advanced cervical cancer, present study was designed to investigate the clinical results of bevacizumab combined with concurrent chemoradiotherapy (CCRT) in local advanced cervical cancer
Timeline
- Start
- 2020-08-01
- Primary completion
- 2021-05-31
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | DDP | Unknown | 40 mg/m2 | Intravenous |
| Subject | DDP | Unknown | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
Indications
No indication recorded.